Literature DB >> 7486896

Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

A L Baltch1, R P Smith, W Ritz.   

Abstract

The susceptibilities of 56 Legionella pneumophila isolates (43 clinical and 15 environmental isolates) to levofloxacin, ofloxacin, erythromycin, and rifampin were studied with buffered charcoal yeast extract (BCYE) agar (inoculum, 10(4) CFU per spot), and the susceptibilities of five isolates were studied with buffered yeast extract (BYE) broth (inoculum, 10(5) CFU/ml). The MICs inhibiting 90% of strains tested on BCYE agar were 0.125, 0.25, 1.0, and < or = 0.004 micrograms/ml for levofloxacin, ofloxacin, erythromycin, and rifampin, respectively. The MICs by the BYE broth dilution method were 1 to 3, 2, 1 to 2, and 1 tube lower than those by the agar dilution method for levofloxacin, ofloxacin, erythromycin, and rifampin, respectively. The MBCs were 1 to 2 tubes higher than the broth dilution MICs for levofloxacin, 1 to 3 tubes higher than the broth dilution MICs for ofloxacin, 1 to 3 tubes higher than the broth dilution MICs for erythromycin, and the same as the broth dilution MICs for rifampin. In kinetic time-kill curve studies, at drug concentrations of 1.0 and 2.0 times the MIC, the most active drugs were levofloxacin and rifampin. At 72 h, concentrations of levofloxacin and rifampin of 2.0 times the MIC demonstrated a bactericidal effect against L. pneumophila. In contrast, at concentrations of 1.0 and 2.0 times the MICs regrowth was observed with ofloxacin and only a gradual decrease in the numbers of CFU per milliliter was observed with erythromycin. Only a minor inhibitory effect was observed with 0.25 or 0.5 time the MICs of all drugs at 24 to 48 h, with regrowth occurring at 72 h. In contrast to erythromycin or ofloxacin plus rifampin at 0.25 time the MICs, only levofloxacin plus rifampin demonstrated synergy. Thus, levofloxacin demonstrated the best inhibitory and bactericidal effects against L. pneumophila when it was studied alone or in a combination with rifampin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486896      PMCID: PMC162803          DOI: 10.1128/AAC.39.8.1661

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

Review 1.  Legionellosis.

Authors:  M H Nguyen; J E Stout; V L Yu
Journal:  Infect Dis Clin North Am       Date:  1991-09       Impact factor: 5.982

2.  Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.

Authors:  S Zanetti; D Ungheri; M Castellani Pastoris; G Fadda
Journal:  Drugs Exp Clin Res       Date:  1987

3.  Antimicrobial activity of imipenem and SCH34343 against Legionella species.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1987-04       Impact factor: 2.803

4.  In vitro activity of carumonam (Ro 17-2301; AMA-1080) versus enteropathogenic and nonfermentative gram-negative rods and Legionella pneumophila.

Authors:  P Hohl; A von Graevenitz; J Zollinger-Iten
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Antimicrobial susceptibility of intracellular Legionella pneumophila.

Authors:  M A Bacheson; H M Friedman; C E Benson
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

6.  Fleroxacin (Ro 23-6240): activity in vitro against 355 enteropathogenic and non-fermentative gram-negative bacilli and Legionella pneumophila.

Authors:  P Hohl; A von Graevenitz; J Zollinger-Iten
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

7.  Legionnaires' disease in patients with associated serious disease.

Authors:  D W Gump; R O Frank; W C Winn; R S Foster; C V Broome; W B Cherry
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

8.  Unresponsiveness of Legionella bozemanii pneumonia to erythromycin administration despite in vitro sensitivity.

Authors:  M M Parker; A M Macher; J H Shelhamer; J E Balow; V Gill; J E Parrillo
Journal:  Am Rev Respir Dis       Date:  1983-11

9.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

10.  Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila.

Authors:  D Havlichek; L Saravolatz; D Pohlod
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

View more
  9 in total

1.  Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.

Authors:  S C Chien; F A Wong; C L Fowler; S V Callery-D'Amico; R R Williams; R Nayak; A T Chow
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Susceptibilities of Legionella spp. to newer antimicrobials in vitro.

Authors:  T Schülin; C B Wennersten; M J Ferraro; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Detection of Legionella pneumophila on clinical samples and susceptibility assessment by flow cytometry.

Authors:  I Faria-Ramos; S Costa-de-Oliveira; J Barbosa; A Cardoso; J Santos-Antunes; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-28       Impact factor: 3.267

4.  Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; M A Franke; P B Michelsen
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 5.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 6.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

7.  Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients.

Authors:  Amparo Sánchez Navarro; Clara-Isabel Colino Gandarillas; Francisco Alvarez Lerma; Y Alcalde Menacho; Alfonso Domínguez-Gil
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

Review 8.  Legionnaires' Disease: Update on Diagnosis and Treatment.

Authors:  Diego Viasus; Valeria Gaia; Carolina Manzur-Barbur; Jordi Carratalà
Journal:  Infect Dis Ther       Date:  2022-05-03

9.  KKL-35 Exhibits Potent Antibiotic Activity against Legionella Species Independently of trans-Translation Inhibition.

Authors:  Romain Brunel; Ghislaine Descours; Isabelle Durieux; Patricia Doublet; Sophie Jarraud; Xavier Charpentier
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.